Prime Medicine (PRME, $4.86) was a top loser over the last three months, falling -2 to $4.86 per share. A.I.dvisor analyzed 914 stocks in the Biotechnology Industry for the 3-month period ending April 29, 2024, and found that of them (4) exhibited an Uptrend while of them (5) demonstrated a Downtrend.